Effect of additional post-BMT KGF administration on mortality (A) and weight loss (B) after allogeneic BMT with a uniformly 100% lethal dose of allogeneic spleen cells. B10.BR recipient mice (n = 8/group) were lethally irradiated (7.5 Gy) on day −1 and infused on day 0 with C57BL/6 BM with 15 × 10⁶ spleen cells (BMS). Groups treated with Cy received 120 mg/kg/d on days −3 and −2. Groups were further segregated into those receiving KGF (5 mg/kg/d) on days −6, −5, and −4 pre-BMT (KGFpre) or those receiving KGF on days −6, −5, and −4 pre-BMT and days 1, 2, and 3 post-BMT (KGFpre&post). In (A), P = .32 and .19 comparing KGF schedules for TBI groups and Cy/TBI groups, respectively. In (B), for BMS + KGFpre versus BMS + KGFpre&post, .05 < P < .1 (⁠$^$⁠) and .01 < P < .05 (*). (▴) BMS + KGFpre, (⧫) BMS + KGFpre and post, (▾) BMS + CY + KGFpre, and (⬗) BMS + CY + KGFpre and post.